Abstract
Large-scale, unbiased combinatorial drug screening has been used to identify effective genotypeselective therapeutic combinations that show promising activity in preclinical models of mutant BRAF and RAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.
Original language | English (US) |
---|---|
Pages (from-to) | 13-19 |
Number of pages | 7 |
Journal | Cancer discovery |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2013 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology